Condition category
Circulatory System
Date applied
29/09/2006
Date assigned
29/09/2006
Last edited
26/08/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr David New

ORCID ID

Contact details

Blood Pressure Unit
Dept of Physiological Medicine
St George's Hospital Medical School
Cranmer Terrace
London
SW17 0RE
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N0236102657

Study information

Scientific title

The Renin Angiotensin System in Essential Hypertension

Acronym

Study hypothesis

To determine and compare the effects of enalapril on sodium balance, atrial pressure and the renin angiotensin aldosrerone system in humans.

Ethics approval

Not provided at time of registration

Study design

Randomised crossover trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Not Specified

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Cardiovascular: Essential hypertension

Intervention

Randomised crossover trial

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

This research is based on the increasing evidence that blockade of the renin-angiotensin-aldosterone system has benefits additional to a fall in blood pressure. There are two major ways of blocking the renin-angiotensin system (RAS), either by inhibiting the enzyme that generates angiotensin II or by blocking the angiotensin receptor, that medicates most of the actions of angiotensin II on its target tissues.
The original and existing aim of this study is to compare the effects of enalapril, an angiotensin converting enzyme inhibitor, against candesartan, a potent and specific angiotensin II receptor blocker, in both normotensive and hypertensive subjects on a normal and moderate sodium restricted diet. Assessment of the contribution of the RAS to blood pressure control and of the mechanism whereby blood pressure falls, will provide important information about the maintenance of blood pressure.

Secondary outcome measures

Not provided at time of registration

Overall trial start date

03/12/2001

Overall trial end date

30/09/2005

Reason abandoned

Eligibility

Participant inclusion criteria

11 subjects and 11 controls

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

22

Participant exclusion criteria

Does not meet inclusion criteria

Recruitment start date

03/12/2001

Recruitment end date

30/09/2005

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Blood Pressure Unit
London
SW17 0RE
United Kingdom

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Sponsor details

The Department of Health
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Hospital/treatment centre

Funder name

St George's Healthcare NHS Trust (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

No External Funding

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

NHS R&D Support Funding (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes